Introduction
Critical Therapeutics is a biopharmaceutical company focused on the development and commercialization of products for respiratory, inflammatory and critical care diseases. It has marketed products such as ZYFLO and ZYFLO CR and is developing Anti-HMGB-1 Mab for rheumatoid arthritis and also formulations of zileuton.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Critical Therapeutics develops products to treat respiratory, inflammatory and critical care diseases. The company' strategic collaborations and licensing agreement are the primary reasons for the rapid development of products and growing revenues. The company's total revenues increased from $1 million in 2003 to $13 million in 2006. Critical Therapeutics' product sales which is entirely from ZYFLO, reported $0.4 million in 2005 and increased by 94% to $7 million in 2006. The company's collaboration revenues recorded $6 million in 2006 compared to $1 million in 2003. Critical Therapeutics' total revenues are forecasted to expand by a CAGR of 53% over the period 2006-2010. The company anticipates product revenues to rise from $7 million in 2006 to $60 million in 2010 at a CAGR of 71%. Revenues from the collaboration agreements are expected to grow with an absolute growth of $7 million during 2006-2010.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.
Report Highlights
[Studien Infos ausblenden]
